A small molecule drug that specifically inactivates the motor function of class-IX myosins, should thus provide a means to disturb the molecular interplay of signalling events that promote cancer cells to acquire a migratory and invasive phenotype, and consequently act as an antimetastatic agent46. The gene discussed is MYH14; the disease is cancer.